Entera Stock Analysis

ENTX
 Stock
  

USD 1.77  0.05  2.75%   

The current slide in stock price could raise concerns from investors as the firm is trading at a share price of 1.77 on 31,700 in volume. The company directors and management have failed to build on market volatilities in July. However, diversifying your overall positions with Entera Bio may protect your principal portfolio during upcoming market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.82. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Entera Bio partners.
Continue to Investing Opportunities.
  
The Entera Bio stock analysis report makes it easy to digest most publicly released information about Entera Bio and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Entera Stock analysis module also helps to analyze the Entera Bio price relationship with some important fundamental indicators such as market cap and management efficiency.

Entera Stock Analysis Notes

About 23.0% of the company shares are held by company insiders. The book value of Entera Bio was currently reported as 0.9. The company recorded a loss per share of 0.83. Entera Bio had not issued any dividends in recent years. Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel. Entera Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 21 people. To learn more about Entera Bio call Adam Gridley at 972 2 532 7151 or check out https://www.enterabio.com.

Entera Bio Quarterly Cost of Revenue

33,000

Entera Bio Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Entera Bio's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Entera Bio or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Entera Bio generated a negative expected return over the last 90 days
Entera Bio has high historical volatility and very poor performance
Entera Bio may become a speculative penny stock
Entera Bio has high likelihood to experience some financial distress in the next 2 years
Entera Bio was previously known as Entera Bio and was traded on NASDAQ Exchange under the symbol ENTXW.
The company reported the previous year's revenue of 482 K. Net Loss for the year was (13.68 M) with profit before overhead, payroll, taxes, and interest of 198 K.
Entera Bio currently holds about 20.11 M in cash with (11.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.7.
Entera Bio has a poor financial position based on the latest SEC disclosures
Roughly 23.0% of the company shares are held by company insiders

Entera Bio Upcoming and Recent Events

Earnings reports are used by Entera Bio to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Entera Bio previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report17th of March 2022
Next Financial Report19th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End17th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Entera Largest EPS Surprises

Earnings surprises can significantly impact Entera Bio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-11-10
2021-09-30-0.11-0.090.0218 
2022-08-11
2022-06-30-0.16-0.110.0531 
2022-05-12
2022-03-31-0.18-0.130.0527 
View All Earnings Estimates

Entera Bio SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Entera Bio prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Entera Bio investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Entera Bio specific information freely available to individual and institutional investors to make a timely investment decision.
11th of August 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Results of Operations and Financial Condition
View
1st of August 2022
Financial Statements and Exhibits. Regulation FD Disclosure
View
18th of July 2022
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
17th of June 2022
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
27th of May 2022
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
View
16th of May 2022
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
12th of May 2022
Regulation FD Disclosure. Results of Operations and Financial Condition
View
8th of March 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Results of Operations and Financial Condition
View

Entera Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 52.39 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Entera Bio's market, we take the total number of its shares issued and multiply it by Entera Bio's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Entera Profitablity

Entera Bio's profitability indicators refer to fundamental financial ratios that showcase Entera Bio's ability to generate income relative to its revenue or operating costs. If, let's say, Entera Bio is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Entera Bio's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Entera Bio's profitability requires more research than a typical breakdown of Entera Bio's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(0.47) (0.51) 
Return on Average Equity(0.60) (0.65) 
Return on Invested Capital 3.64  5.50 
Return on Sales(21.45) (23.14) 

Management Efficiency

The entity has return on total asset (ROA) of (41.97) % which means that it has lost $41.97 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (99.97) %, meaning that it created substantial loss on money invested by shareholders. Entera Bio management efficiency ratios could be used to measure how well entera bio manages its routine affairs as well as how well it operates its assets and liabilities. Return on Invested Capital is likely to rise to 5.50 in 2022, whereas Return on Average Assets are likely to drop (0.51)  in 2022. Entera Bio Assets Non Current are fairly stable at the moment as compared to the past year. Entera Bio reported Assets Non Current of 658,000 in 2021. Goodwill and Intangible Assets is likely to rise to about 556.5 K in 2022, whereas Total Assets are likely to drop slightly above 21.9 M in 2022.
Last ReportedProjected for 2022
Book Value per Share 0.86  0.93 
Enterprise Value over EBIT(4.00) (4.11) 
Enterprise Value over EBITDA(4.43) (4.54) 
Price to Book Value 3.59  3.61 
Tangible Assets Book Value per Share 0.99  1.12 
Enterprise Value54 M45.7 M
Tangible Asset Value26 M21.7 M

Technical Drivers

As of the 16th of August 2022, Entera Bio shows the mean deviation of 4.13, and Coefficient Of Variation of (23,845). Entera Bio technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Entera Bio, which can be compared to its rivals. Please confirm Entera Bio variance and potential upside to decide if Entera Bio is priced favorably, providing market reflects its regular price of 1.77 per share. Please also check Entera Bio total risk alpha, which is currently at (0.47) to verify the company can sustain itself at a future point.

Entera Bio Price Movement Analysis

The output start index for this execution was thirty-two with a total number of output elements of twenty-nine. The MESA Adaptive Moving Average indicator adapts to Entera Bio price movement based on the rate change of phase as measured by the Hilbert Transform Discriminator.
.

Entera Bio Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Entera Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Entera Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Entera Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Entera Bio Predictive Daily Indicators

Entera Bio intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Entera Bio stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Entera Bio Forecast Models

Entera Bio time-series forecasting models is one of many Entera Bio's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Entera Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Entera Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Entera Bio prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Entera shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Entera Bio. By using and applying Entera Stock analysis, traders can create a robust methodology for identifying Entera entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin(21.35) (23.04) 
Gross Margin 0.35  0.36 
Profit Margin(21.34) (23.03) 
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel. Entera Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 21 people.

Current Entera Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Entera analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Entera analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
11.0Strong Buy3Odds
Entera Bio current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Entera analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Entera stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Entera Bio, talking to its executives and customers, or listening to Entera conference calls.
Entera Analyst Advice Details

Entera Stock Analysis Indicators

Entera Bio stock analysis indicators help investors evaluate how Entera Bio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Entera Bio shares will generate the highest return on investment. By understating and applying Entera Bio stock analysis, traders can identify Entera Bio position entry and exit signals to maximize returns.
Quick Ratio8.71
Fifty Two Week Low1.3100
Revenue Growth-56.70%
Shares Short Prior Month126.66k
Average Daily Volume Last 10 Day21.16k
Average Daily Volume In Three Month32.45k
Shares Percent Shares Out0.27%
Gross Margins26.56%
Short Percent Of Float0.32%
Forward Price Earnings-2.64
Float Shares18.95M
Fifty Two Week High5.3900
Enterprise Value To Ebitda-2.64
Fifty Day Average1.6964
Two Hundred Day Average2.4775
Enterprise Value To Revenue74.71
Continue to Investing Opportunities. Note that the Entera Bio information on this page should be used as a complementary analysis to other Entera Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Complementary Tools for Entera Stock analysis

When running Entera Bio price analysis, check to measure Entera Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entera Bio is operating at the current time. Most of Entera Bio's value examination focuses on studying past and present price action to predict the probability of Entera Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Entera Bio's price. Additionally, you may evaluate how the addition of Entera Bio to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Is Entera Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entera Bio. If investors know Entera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entera Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
52.4 M
Quarterly Revenue Growth YOY
-0.57
Return On Assets
-0.42
Return On Equity
-1.0
The market value of Entera Bio is measured differently than its book value, which is the value of Entera that is recorded on the company's balance sheet. Investors also form their own opinion of Entera Bio's value that differs from its market value or its book value, called intrinsic value, which is Entera Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entera Bio's market value can be influenced by many factors that don't directly affect Entera Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entera Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Entera Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entera Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.